{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}],"title":"5 MU/M^2IFN alpha"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"10 MU/M^2 IFN alpha"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"20 MU/M^2IFN alpha (RP2D)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Number of patients treated at each of the three possible dose levels of Interferon α (5 MU/m\\^2, 10 MU/m\\^2 or 20 MU/m\\^2) during the Phase 1 portion of the study.","groups":[{"description":"α DC1 vaccine and\n\nChemokine Modulatory Regimen:\n\nCelecoxib: Administered at 200 mg, once a day orally (T-TH) Rintatolimod: Intravenous infusion of 200 mg (Wed \\& and Fri, only) Interferon α -2b: Intravenous infusion - 5 MU/m\\^2, 10 MU/m\\^2 or 20 MU/m\\^2 (T-Fri)","id":"OG000","title":"Phase 1- αDC1 Vaccine +1 Cycle of Chemokine Modulatory Regimen"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only includes patients participating in the Phase 1 portion.","reportingStatus":"POSTED","timeFrame":"Up to 24 weeks","title":"Recommended Phase 2 Dose (RP2D) (Phase 1)","type":"PRIMARY","unitOfMeasure":"Participants"}